Obese Adults with Cardiovascular Disease Evaluated in a Novel Cardiometabolic Clinic

Overview

About this study

The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- BMI ≥30 kg/m2

- At least one of the following CVD: atrial fibrillation (AF), coronary artery disease
(CAD), HFpEF (heart failure with preserved ejection fraction), HFrEF (heart failure
with reduced ejection fraction), ACHD (adult congenital heart disease), or valvular
heart disease

- Patients evaluated in the Cardiometabolic clinic and treated with or without weight
loss medications

- Willingness to complete questionnaires/surveys

- Ability to complete monthly self-assessments at home

Exclusion Criteria:

- BMI <30 kg/m2

- Pregnancy or lactating women

- Hemodynamically unstable CVD

- Active malignancy

- Autoimmune or systemic inflammatory diseases

- Severe renal or hepatic failure

- Being considered unsafe to participate as determined by the study physician

- Taking medications affecting weight or energy intake/energy expenditure in the last 6
months, including weight loss medications, antipsychotic medications, or other
medications as determined by the study NP or physician

- Patients with active psychosis, mania, or substance use disorders

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/14/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kyla Lara-Breitinger, M.D.

Open for enrollment

Contact information:

Preventive Heart Research Team

(507) 538-7425

rstcvruprevent@mayo.edu

More information

Publications

Publications are currently not available